Invesaro

Stocks Consumer discretionary HLN

NYSE · Consumer discretionary

Haleon plc (HLN)

Haleon plc reported revenue of £11B in fiscal 2025, down 1.8% from a year earlier. Net income was £1.7B, a net margin of 15.1%. Operating cash flow minus capital spending left £2.3B of free cash flow in fiscal 2025. At December 31, 2025 it held £1.3B in cash against £8.6B of debt.

Watch HLN in 60 seconds
Price
$9.17
-0.97% on the day · September 28, 2026
52-week range $8.65 to $11.28
Market cap
$40.8B
Revenue (FY2025)
£11B
-1.8% year on year
Net margin
15.1%

What Haleon plc does

Haleon manufactures and markets over-the-counter consumer health products. Its product lines include oral care items, pain relief medications, respiratory remedies, and dietary supplements, sold to retail pharmacies, supermarkets, and general retailers under brands such as Sensodyne, Advil, and Centrum. Its shares trade on NYSE under the ticker HLN.

Revenue and profit by year

Revenue
FY20: £9.9B £9.9B FY20FY22: £9.5B £9.5B FY22FY22: £10.9B £10.9B FY22FY23: £11.3B £11.3B FY23FY24: £11.2B £11.2B FY24FY25: £11B £11B FY25
Net income
FY20: £1.1B £1.1B FY20FY22: £1.4B £1.4B FY22FY22: £1.1B £1.1B FY22FY23: £1B £1B FY23FY24: £1.4B £1.4B FY24FY25: £1.7B £1.7B FY25

Fiscal years as reported in annual reports. Amounts in GBP.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025£11B£2.4B£1.7B£0.19£2.3B
2024£11.2B£2.2B£1.4B£0.16£2.1B
2023£11.3B£2B£1B£0.11£1.9B
2022£10.9B£1.8B£1.1B£0.12£1.8B
2022£9.5B£1.6B£1.4B£0.15£1.1B
2020£9.9B£1.6B£1.1B£0.12£1.2B

Full financial statements: income, balance sheet and cash flow

Where HLN ranks in Consumer discretionary

Revenue growth-1.8%
#679 of 950 in Consumer discretionary · Bottom 29%
Net margin15.1%
#115 of 966 in Consumer discretionary · Top 12%
Free cash flow margin21.0%
#59 of 850 in Consumer discretionary · Top 7%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Consumer discretionary

Latest SEC filings

What Haleon plc has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 24, 2026
    Foreign issuer update 6-K
  2. September 18, 2026
    Foreign issuer update 6-K
  3. September 1, 2026
    Foreign issuer update 6-K
  4. August 21, 2026
    Foreign issuer update 6-K
  5. August 19, 2026
    Foreign issuer update 6-K
  6. August 19, 2026
    Foreign issuer update 6-K
  7. August 17, 2026
    Foreign issuer update 6-K
  8. August 13, 2026
    Securities offering prospectus 424B5
  9. August 13, 2026
    Foreign issuer update 6-K
  10. August 13, 2026
    Offering term sheet FWP

Recent insider filings (Forms 3, 4 and 144): 3, the latest on December 29, 2023. Insider transactions on SEC

Insider trades

What the people running Haleon plc did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns HLN

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

HolderOf classSharesFiled
Dodge & Cox13G, passive 6.5% 233,276,589 November 13, 2024
Wellington Management Group LLP13G, passive with 2 related filers 5% 443,046,686 February 10, 2026

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

No insider reported holdings on a Form 4 in the last 12 months.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about HLN

What does Haleon plc do?

Haleon manufactures and markets over-the-counter consumer health products. Its product lines include oral care items, pain relief medications, respiratory remedies, and dietary supplements, sold to retail pharmacies, supermarkets, and general retailers under brands such as Sensodyne, Advil, and Centrum. Its shares trade on NYSE under the ticker HLN.

Is Haleon plc profitable?

Yes. In fiscal 2025 it reported net income of £1.7B on revenue of £11B, a net margin of 15.1%.

How much revenue does Haleon plc make?

In fiscal 2025 Haleon plc reported revenue of £11B. That is 1.8% less than a year earlier.

When did Haleon plc last report?

Its newest filing of any kind is the foreign issuer update from September 24, 2026.

Similar companies

CL
Colgate Palmolive Co
KVUE
Kenvue Inc.
EL
Estee Lauder Companies Inc
COTY
Coty Inc.
EPC
EDGEWELL PERSONAL CARE Co
ELF
e.l.f. Beauty, Inc.

Compare HLN with

Compare HLN with any company

Follow HLN

Get an email when Haleon plc files with the SEC: results, executive changes, material agreements and annual reports.

Follow HLN: get an email when it files

Where the numbers come from

Financial figures are the values Haleon plc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.